Status:
UNKNOWN
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Coronavirus Disease 2019 (COVID-19)
Post-Exposure Prophylaxis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background: The rapid spread and high infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) makes identifying an effective prophylaxis agent highly important. One of the important...
Detailed Description
BACKGROUND: A novel coronavirus referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) was identified as the causative agent for the pandemic coronavirus disease 2019 (COVID-19). ...
Eligibility Criteria
Inclusion
- Adult participant (\>18 years)
- HCW who had a contact without adequate personal protective equipment (PPE) with a confirmed COVID-19 patient.
- Time between exposure to randomization no longer than 72 hours.
- Informed consent from participant
Exclusion
- Symptoms compatible with COVID-19 upon randomization
- Known allergy to HCQ or chloroquine
- History of any arrhythmia.
- Severely reduced LV function (Ejection fraction\<30%)
- Retinopathy
- Pregnancy or breast feeding
- Concomitant treatment with azithromycin, flecainide, amiodarone, digoxin, procainamide, propafenone, thioridazine, pimozide.
- Chronic chloroquine/ HCQ treatment
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
582 Patients enrolled
Trial Details
Trial ID
NCT04438837
Start Date
July 1 2020
End Date
June 1 2022
Last Update
July 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Health Care Campus
Haifa, Israel